contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-live-presentation-of-senzimes-first-quarter-2024-report

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Senzime is a medical technology company. The company develops technology solutions that make it possible to follow biochemical and physiological processes before, during and after surgery. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. In addition to the main services, digital systems are also offered and developed for monitoring patients' conditions during anesthesia treatment. The company's head office is located in Uppsala.

Senzime

Senzime invites investors, analysts, and media to a webcast presentation of the first quarter report for 2024 on May 7, 10:00 CEST. The report will be published during the morning of the same...

<div class="mfn-preamble"><p><strong>Senzime invites investors, analysts, and media to a webcast presentation of the first quarter report for 2024 on May 7, 10:00 CEST. The report will be published during the morning of the same day.</strong></p></div><div class="mfn-body"><p>The presentation will be held by Philip Siberg, CEO of Senzime, and after the presentation, there will be a Q&amp;A session moderated by analyst at Carnegie Investment Bank. The presentation will be held in English.<br>&nbsp;<br>Date and time: Tuesday, May 7, 10:00-10:30 am CEST<br>&nbsp;<br>The presentation can be followed live via webcast at&nbsp;<a rel="noopener" href="https://www.youtube.com/watch?v=TukFP5Laenw">https://www.youtube.com/watch?v=TukFP5Laenw</a>.<br><br>After the presentation, a recording of the webcast will be available at <a rel="noopener" href="https://www.senzime.com/investors">senzime.com/investors</a>.</p></div><div class="mfn-footer mfn-f23cb96ba75a"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Philip Siberg, CEO of Senzime AB<br>Phone: +46 (0) 707 90 67 34, e-mail:&nbsp;<a rel="noopener" href="mailto:philip.siberg@senzime.com">philip.siberg@senzime.com</a><br>&nbsp;<br>Slavoljub Grujicic, CFO<br>Phone: +46 (0) 76 306 60 11, e-mail: <a rel="noopener" href="mailto:slavoljub.grujicic@senzime.com">slavoljub.grujicic@senzime.com</a></p></div><div class="mfn-footer mfn-about mfn-51570c1d0876"><p><strong class="mfn-heading-1">About Senzime</strong></p><hr><p>Senzime, headquartered in Sweden, is a leading medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. The company provides an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for accurate monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.</p><p>Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (Nasdaq: SEZI) and cross-traded in the US on the OTCQX market (OTCQX: SNZZF). More information is available at <a rel="noopener" href="https://senzime.com/">senzime.com</a>.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/c496ab82-da4a-4346-ac7f-a34b84a37faa/invitation-to-live-presentation-of-senzimes-first-quarter-2024-report.pdf" class="mfn-generated mfn-primary">Invitation to live presentation of Senzime’s first quarter 2024 report</a></p></div>

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!